Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 4 versus PREDNISOLONE.
Head-to-head clinical analysis: DEXONE 4 versus PREDNISOLONE.
DEXONE 4 vs PREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, inhibition of phospholipase A2, and reduction of prostaglandin and leukotriene synthesis.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
Initial adult dose: 5-60 mg orally, intramuscularly, or intravenously daily, divided into 2-4 doses; maintenance: 2.5-15 mg daily.
None Documented
None Documented
Clinical Note
moderatePrednisolone + Digoxin
"Prednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisolone + Digitoxin
"Prednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Terminal half-life: 2.1-3.5 hours in adults; prolonged in hepatic impairment (up to 12 hours) or with concurrent estrogen use.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Renal (primarily as glucuronide and sulfate conjugates; <20% as unchanged prednisolone); biliary/fecal (minor, <5%).
Category C
Category D/X
Corticosteroid
Corticosteroid